These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 8895175)

  • 21. [Eosinophilia-myalgia syndrome. The clinical spectrum expands].
    Schnabel A; Gross WL
    Z Rheumatol; 1992; 51(1):1-2. PubMed ID: 1574930
    [No Abstract]   [Full Text] [Related]  

  • 22. [A lesson on the purity of pharmaceutical products derived from biotechnology: eosinophilia-myalgia syndrome].
    Boll Chim Farm; 1995; 134(7):394-5. PubMed ID: 7546544
    [No Abstract]   [Full Text] [Related]  

  • 23. Tryptophan produced by Showa Denko and epidemic eosinophilia-myalgia syndrome.
    Kilbourne EM; Philen RM; Kamb ML; Falk H
    J Rheumatol Suppl; 1996 Oct; 46():81-8; discussion 89-91. PubMed ID: 8895184
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Eosinophilia-myalgia syndrome among the non-L-tryptophan users and pre-epidemic cases.
    Sullivan EA; Staehling N; Philen RM
    J Rheumatol; 1996 Oct; 23(10):1784-7. PubMed ID: 8895159
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The eosinophilia-myalgia syndrome: opportunities realized and missed.
    Hertzman PA
    J Rheumatol; 1996 Oct; 23(10):1679-81. PubMed ID: 8895138
    [No Abstract]   [Full Text] [Related]  

  • 26. Epidemiologic studies of the association of L-tryptophan with the eosinophilia-myalgia syndrome: a critique.
    Shapiro S
    J Rheumatol Suppl; 1996 Oct; 46():44-58; discussion 58-9. PubMed ID: 8895181
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Presence of peak X and related compounds: the reported contaminant in case related 5-hydroxy-L-tryptophan associated with eosinophilia-myalgia syndrome.
    Johnson KL; Klarskov K; Benson LM; Williamson BL; Gleich GJ; Naylor S
    J Rheumatol; 1999 Dec; 26(12):2714-7. PubMed ID: 10606395
    [No Abstract]   [Full Text] [Related]  

  • 28. [Eosinophilic myalgia from L-tryptophan].
    Hardelin D; Saviuc P; Mallaret M; Brousse P; Danel V
    J Toxicol Clin Exp; 1990 Oct; 10(6):409-12. PubMed ID: 2130184
    [No Abstract]   [Full Text] [Related]  

  • 29. Gastrointestinal involvement in L-tryptophan (L-Trp) associated eosinophilia-myalgia syndrome (EMS).
    De Schryver-Kecskemeti K; Bennert KW; Cooper GS; Yang P
    Dig Dis Sci; 1992 May; 37(5):697-701. PubMed ID: 1563309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. L-tryptophan and the eosinophilia-myalgia syndrome: a clinical and laboratory study.
    McKeon P; Swanwick G; Manley P
    Acta Psychiatr Scand; 1994 Dec; 90(6):451-4. PubMed ID: 7892779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Current aspects in discussion of eosinophilia-myalgia syndrome].
    Zipp F; Demisch L
    Nervenarzt; 1992 Apr; 63(4):249-53. PubMed ID: 1594093
    [No Abstract]   [Full Text] [Related]  

  • 32. Reduced severity of eosinophilia-myalgia syndrome associated with the consumption of vitamin-containing supplements before illness.
    Hatch DL; Goldman LR
    Arch Intern Med; 1993 Oct; 153(20):2368-73. PubMed ID: 8215741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Search for contaminant in EMS outbreak goes slowly.
    Swinbanks D; Anderson C
    Nature; 1992 Jul; 358(6382):96. PubMed ID: 1614552
    [No Abstract]   [Full Text] [Related]  

  • 34. Eosinophilia myalgia syndrome.
    Blackburn WD
    Semin Arthritis Rheum; 1997 Jun; 26(6):788-93. PubMed ID: 9213377
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The eosinophilia-myalgia syndrome--guidelines for patient care.
    Hertzman PA; Kaufman LD; Love LA; Mease PJ; Philen RM; Pincus T; Rosenberg NL; Silver R; Varga J; Clauw DJ
    J Rheumatol; 1995 Jan; 22(1):161-3. PubMed ID: 7699664
    [No Abstract]   [Full Text] [Related]  

  • 36. Eosinophilia-myalgia syndrome in a child with phenylketonuria.
    Springer MA; Bock HG; Philen RM; Hill RH; Crawford LV
    Pediatrics; 1992 Oct; 90(4):630-3. PubMed ID: 1408523
    [No Abstract]   [Full Text] [Related]  

  • 37. Fibromyalgia, psychiatric disorders, and assessment of the longterm outcome of eosinophilia-myalgia syndrome.
    Hudson JI; Pope HG; Carter WP; Daniels SR
    J Rheumatol Suppl; 1996 Oct; 46():37-42; discussion 42-3. PubMed ID: 8895180
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structural characterization of contaminants found in commercial preparations of melatonin: similarities to case-related compounds from L-tryptophan associated with eosinophilia-myalgia syndrome.
    Williamson BL; Tomlinson AJ; Mishra PK; Gleich GJ; Naylor S
    Chem Res Toxicol; 1998 Mar; 11(3):234-40. PubMed ID: 9544622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eosinophilia-myalgia syndrome. Status of patients at onset and after four years of disease.
    Criswell LA; Pincus T
    Adv Exp Med Biol; 1996; 398():371-2. PubMed ID: 8906291
    [No Abstract]   [Full Text] [Related]  

  • 40. L-tryptophan and eosinophilia-myalgia syndrome.
    Shapiro S
    Lancet; 1994 Sep; 344(8925):817-9. PubMed ID: 7916094
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.